About ImmunoBiochem
ImmunoBiochem is a Healthcare company based in Toronto (Canada) founded in 2007 by Anton Neschadim. It operates as a proprietary ADCs are developed against intracellular cancer targets. The company has 4 employees. Its chief executive is Anton Neschadim. ImmunoBiochem offers products and services including Biological Therapeutics and Antibody-Drug Conjugates. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is ImmunoBiochem Corporation. Similar companies include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen and 2 more; 7 of its 7 listed similar companies have raised funding.
Company details
ImmunoBiochem was founded in 2007 in Toronto, Canada, and operates in the biotechnology sector focused on oncology. A proprietary platform is utilized to create antibody-drug conjugates (ADCs) that target intracellular tumor antigens, distinguishing them from conventional ADCs. Lead candidates IMB-101 and IMB-102, aimed at solid malignancies, are advanced through preclinical development stages.
- Headquarters Toronto, Canada
- Employees 4
- Founders Anton Neschadim
- SectorsHealthcare
- Email••••••••
- Website immunobiochem.com
- Social LinkedIn X Facebook
- Legal Name Immunobiochem Corporation
- Employee Count4
Products & Services of ImmunoBiochem
ImmunoBiochem offers a comprehensive portfolio of products and services, including Biological Therapeutics and Antibody-Drug Conjugates.
Develops targeted therapies for cancer using AI and assays.
Creates conjugates for selective delivery to tumor cells.
People of ImmunoBiochem
1 people are tracked at ImmunoBiochem (1 in leadership); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Anton Neschadim | Founder & CEO | Leadership |
Complete people profiles for ImmunoBiochem
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Similar companies to ImmunoBiochem
ImmunoBiochem has 7 listed similar companies in our database, 7 of them funded. They include Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed similar companies of ImmunoBiochem
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ImmunoBiochem
Websites that share an audience with ImmunoBiochem (immunobiochem.com).
Websites whose visitors overlap most with ImmunoBiochem. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hum-molgen.org | 100% | – | #11,260,715 | View details | |
| asbmb.org | 100% | – | #294,924 | View details |
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as ImmunoBiochem (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immunobiochem
Complete news archive for ImmunoBiochem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImmunoBiochem
ImmunoBiochem was founded in 2007.
ImmunoBiochem is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Anton Neschadim is the current CEO of ImmunoBiochem. They have also founded this company.
ImmunoBiochem has 4 employees.
ImmunoBiochem was founded in 2007 in Toronto, Canada, and operates in the biotechnology sector focused on oncology. A proprietary platform is utilized to create antibody-drug conjugates (ADCs) that target intracellular tumor antigens, distinguishing them from conventional ADCs. Lead candidates IMB-101 and IMB-102, aimed at solid malignancies, are advanced through preclinical development stages.
ImmunoBiochem's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
ImmunoBiochem offers Biological Therapeutics and Antibody-Drug Conjugates.
ImmunoBiochem operates through Immunobiochem Corporation.